Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.39 +3.09%

+$0.08 today

Market cap
$270.48M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.69M

Average 3.81M

ALT Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Altimmune, Inc.NASDAQ: ALT

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $23K fell 20.7% year over year, ahead of the -33.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 11.5% from the prior quarter. Over 3 fiscal years it compounded at -39.0% a year.

Context

  • Depreciation & amortization amounted to 273.2% of revenue in FY2025, down 916.8 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -20.7% holds above the trailing-twelve-month pace of -33.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$23K-11.5% QoQ
Last fiscal yearDec 2025
$112K-52.9% YoY
LTMMar 2026
$106K-33.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.7%——
1 year-52.9%——
3-year CAGR-39.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
112K USD
Year-over-year change
-52.9%
4-year CAGR
-32.9%

Depreciation & Amortization vs competitors

How ALT compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -33.8% is the 5th highest of 8, against a peer median of -10.0%.
  • Depreciation & amortization amounts to 294.4% of revenue for ALT, versus a peer median of 7.1%.
ALT Competitors
Depreciation & Amortization for ALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$11.62M USD-10.0%+19.9%17.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$4.93M USD+55.9%+19.6%7.1%
IVAInventiva S.A.FY2025€2.8M EUR-46.2%+47.6%62.4%
GPCRStructure Therapeutics Inc.LTM Jun 2026$1.92M USD+74.2%+141.5%—
BMEABiomea Fusion, Inc.LTM Mar 2026$1.02M USD-43.2%+26.8%—
ASMBAssembly Biosciences, Inc.LTM Mar 2026$122K USD-6.2%-36.3%0.2%
ALTAltimmune, Inc.LTM Mar 2026$106K USD-33.8%-39.0%294.4%
ABUSArbutus Biopharma CorporationLTM Mar 2026$44K USD-96.8%-36.6%0.0%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding ALT) —-10.0%+19.9%7.1%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.41M(68K)426K20K41K
Cost of Revenue00000
Gross Profit4.41M(68K)426K20K41K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development74.54M70.54M65.8M82.23M66.43M
Selling, General & Admin15.41M17.13M18.14M20.97M28.1M
Operating Expenses101.32M87.67M96.36M103.19M94.53M
Depreciation & Amortization551K493K477K238K112K
EBITDA(96.53M)(84.41M)(87.94M)(94.81M)(87.03M)
EBITDA Margin-2189.0%124130.9%-20642.0%-474060.0%-212258.5%
Operating Income(96.91M)(87.74M)(95.93M)(103.17M)(94.49M)
Operating Margin-2197.6%129029.4%-22518.5%-515860.0%-230461.0%
Interest Income203K2.87M7.35M8.07M7.54M
Interest Expense5K8K35K9K1.64M
Other Income / Expenses(176K)2.83M7.48M8.11M5.72M
Income Before Tax(97.09M)(84.91M)(88.45M)(95.06M)(88.77M)
Pre-Tax Margin-2201.6%124867.6%-20762.2%-475295.0%-216522.0%
Income Tax Expense0(197K)00(681K)
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Net Margin-2201.6%124577.9%-20762.2%-475295.0%-214861.0%
EPS (Basic)(2.35)(1.81)(1.66)(1.34)(1.00)
EPS (Diluted)(2.35)(1.81)(1.66)(1.34)(1.00)
Weighted Avg Shares41.28M46.93M53.25M71M88.1M
Weighted Avg Shares (Diluted)41.28M46.93M53.25M71M88.1M

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.